ORION CORPORATION MANAGERS’ TRANSACTIONS
____________________________________________
Person subject to the notification requirement
Position: Other senior manager
(X) Legal person
Issuer:
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 74370029VAHCXDR7B745_20210723101124_5
____________________________________________
Transaction date:
Venue:
Instrument type: SHARE
ISIN: FI0009014377
Nature of the transaction: DISPOSAL
Transaction details
(1): Volume: 1,000 Unit price:
(2): Volume: 1,000 Unit price:
(3): Volume: 5,000 Unit price:
(4): Volume: 5,700 Unit price:
Aggregated transactions
(4): Volume: 12,700 Volume weighted average price:
President and CEO | SVP, Corporate Functions |
Publisher:
Communications
Orionintie 1A, FI-02200 Espoo,
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to
© OMX, source